Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research note released on Saturday.

Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a buy rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. Needham & Company LLC reduced their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Tuesday, August 13th. Finally, Bank of America cut Esperion Therapeutics from a neutral rating to an underperform rating and dropped their target price for the company from $2.90 to $2.50 in a research report on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $8.17.

Esperion Therapeutics Stock Down 5.6 %

ESPR opened at $2.04 on Friday. The stock’s fifty day moving average is $1.84 and its two-hundred day moving average is $2.19. The company has a market capitalization of $386.50 million, a P/E ratio of -2.06 and a beta of 1.00. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to the consensus estimate of $51.90 million. Equities analysts anticipate that Esperion Therapeutics will post -0.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC lifted its position in Esperion Therapeutics by 105.9% during the third quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 39,635 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Esperion Therapeutics by 104.8% during the 2nd quarter. Mackenzie Financial Corp now owns 35,254 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 18,036 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter worth $159,000. Deerfield Management Company L.P. Series C purchased a new position in Esperion Therapeutics during the 2nd quarter worth $148,000. Finally, Marshall Wace LLP grew its stake in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after buying an additional 2,087,635 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.